Cyrus Biotechnology, based in Seattle, WA, is a pre-clinical-stage biotech company founded out of the protein design laboratory of Prof. David Baker at the University of Washington. Specializing in AI and big data-driven protein reengineering, Cyrus utilizes deep mutational scanning to create novel biologics for autoimmune, infectious disease, and oncology.
With a focus on optimizing therapeutic efficacy and safety, Cyrus collaborates with top global Pharma firms and has established a biochemistry laboratory for internal and partnered programs. The company's innovative platform combines physics-based modeling with AI to modify natural proteins, addressing serious unmet medical needs in various indications such as autoimmune disease, gene therapy, metabolic disorders, and COVID-19.
Generated from the website